Skip to main content
Top
Published in: Current Heart Failure Reports 4/2012

01-12-2012 | Epidemiology of Heart Failure (J Butler, Section Editor)

Prevalence and Importance of Comorbidities in Patients With Heart Failure

Authors: Filippos K. Triposkiadis, John Skoularigis

Published in: Current Heart Failure Reports | Issue 4/2012

Login to get access

Abstract

Heart failure (HF), being a disease of the elderly, is associated with several noncardiac comorbidities, defined as chronic conditions coexisting with HF that play an integral role in its development, progression, and response to treatment. These include pulmonary dysfunction, sleep-disordered breathing, renal dysfunction, liver dysfunction, anaemia, thyroid disorders, diabetes mellitus, skeletal myopathy, depression, and cognitive impairment. The noncardiac comorbidity burden is higher and associated with higher non-HF hospitalizations in patients with HF and preserved, as compared with those with HF and reduced, left-ventricular ejection fraction. Since chronic inflammation is a characteristic feature of both HF and the coexisting morbidities, it may play a pivotal role in their development, progression, and interactions.
Literature
1.
go back to reference Roger VL, Go AS, Lloyd-Jones DM, et al. Heart disease and stroke statistics–2011 update: A report from the american heart association. Circulation. 2011;123:e18–e209.PubMedCrossRef Roger VL, Go AS, Lloyd-Jones DM, et al. Heart disease and stroke statistics–2011 update: A report from the american heart association. Circulation. 2011;123:e18–e209.PubMedCrossRef
2.
3.
go back to reference • Triposkiadis F, Starling RC, Boudoulas H, et al. The cardiorenal syndrome in heart failure: Cardiac? Renal? Syndrome? Hear Fail Rev. 2012;17:355–66. Interesting review article emphasizing the bidirectional associations between heart failure and coexisting morbidities and the lack of evidence regarding the presence of the cardiorenal syndrome.CrossRef • Triposkiadis F, Starling RC, Boudoulas H, et al. The cardiorenal syndrome in heart failure: Cardiac? Renal? Syndrome? Hear Fail Rev. 2012;17:355–66. Interesting review article emphasizing the bidirectional associations between heart failure and coexisting morbidities and the lack of evidence regarding the presence of the cardiorenal syndrome.CrossRef
4.
go back to reference •• Ather S, Chan W, Bozkurt B, et al. Impact of noncardiac comorbidities on morbidity and mortality in a predominantly male population with heart failure and preserved versus reduced ejection fraction. J Am Coll Cardiol. 2012;59:998–1005. Important study which demonstrated a higher noncardiac comorbidity burden associated with higher non-heart failure (HF) hospitalizations in patients with HF and preserved (n = 2,843) vs. those with HF and depressed (n = 6,599) left ventricular ejection fraction during a 2-year follow-up.PubMedCrossRef •• Ather S, Chan W, Bozkurt B, et al. Impact of noncardiac comorbidities on morbidity and mortality in a predominantly male population with heart failure and preserved versus reduced ejection fraction. J Am Coll Cardiol. 2012;59:998–1005. Important study which demonstrated a higher noncardiac comorbidity burden associated with higher non-heart failure (HF) hospitalizations in patients with HF and preserved (n = 2,843) vs. those with HF and depressed (n = 6,599) left ventricular ejection fraction during a 2-year follow-up.PubMedCrossRef
5.
go back to reference Waxman AB. Pulmonary function test abnormalities in pulmonary vascular disease and chronic heart failure. Clinics in Chest Medicine. 2001;22:751–8.PubMedCrossRef Waxman AB. Pulmonary function test abnormalities in pulmonary vascular disease and chronic heart failure. Clinics in Chest Medicine. 2001;22:751–8.PubMedCrossRef
6.
go back to reference Gehlbach BK, Geppert E. The pulmonary manifestations of left heart failure. Chest. 2004;125:669–82.PubMedCrossRef Gehlbach BK, Geppert E. The pulmonary manifestations of left heart failure. Chest. 2004;125:669–82.PubMedCrossRef
7.
go back to reference Mettauer B, Lampert E, Charloux A, et al. Lung membrane diffusing capacity, heart failure, and heart transplantation. Am J Cardiol. 1999;83:62–7.PubMedCrossRef Mettauer B, Lampert E, Charloux A, et al. Lung membrane diffusing capacity, heart failure, and heart transplantation. Am J Cardiol. 1999;83:62–7.PubMedCrossRef
8.
go back to reference • Szwejkowski BR, Elder DH, Shearer F, et al. Pulmonary hypertension predicts all-cause mortality in patients with heart failure: A retrospective cohort study. Eur J Hear Fail. 2012;14:162–7. Record linkage study in Tayside, Scotland utilizing the Tayside echocardiogram database (>50,000 echocardiograms).Patients were included in the analysis if they had left ventricular systolic dysfunction, right ventricular systolic pressure (RVSP) measurement, and a loop diuretic prescription (provided not more than 1 year prior to echocardiogram). Pulmonary hypertension predicted all-cause mortality in this heterogeneous group of patients with heart failure with each 5 mmHg rise in RVSP was associated with a 6 % increased risk of death.CrossRef • Szwejkowski BR, Elder DH, Shearer F, et al. Pulmonary hypertension predicts all-cause mortality in patients with heart failure: A retrospective cohort study. Eur J Hear Fail. 2012;14:162–7. Record linkage study in Tayside, Scotland utilizing the Tayside echocardiogram database (>50,000 echocardiograms).Patients were included in the analysis if they had left ventricular systolic dysfunction, right ventricular systolic pressure (RVSP) measurement, and a loop diuretic prescription (provided not more than 1 year prior to echocardiogram). Pulmonary hypertension predicted all-cause mortality in this heterogeneous group of patients with heart failure with each 5 mmHg rise in RVSP was associated with a 6 % increased risk of death.CrossRef
9.
go back to reference Chen Y, Guo H, Xu D, Xu X, et al. Left ventricular failure produces profound lung remodeling and pulmonary hypertension in mice: Heart failure causes severe lung disease. Hypertension. 2012;59:1170–8.PubMedCrossRef Chen Y, Guo H, Xu D, Xu X, et al. Left ventricular failure produces profound lung remodeling and pulmonary hypertension in mice: Heart failure causes severe lung disease. Hypertension. 2012;59:1170–8.PubMedCrossRef
10.
go back to reference Haddad F, Kudelko K, Mercier O, et al. Pulmonary hypertension associated with left heart disease: Characteristics, emerging concepts, and treatment strategies. Prog Cardiovasc Dis. 2011;54:154–67.PubMedCrossRef Haddad F, Kudelko K, Mercier O, et al. Pulmonary hypertension associated with left heart disease: Characteristics, emerging concepts, and treatment strategies. Prog Cardiovasc Dis. 2011;54:154–67.PubMedCrossRef
11.
go back to reference Hefke T, Zittermann A, Fuchs U, et al. Bosentan effects on hemodynamics and clinical outcome in heart failure patients with pulmonary hypertension awaiting cardiac transplantation. Thorac Cardiovasc Surg. 2012;60:26–34.PubMedCrossRef Hefke T, Zittermann A, Fuchs U, et al. Bosentan effects on hemodynamics and clinical outcome in heart failure patients with pulmonary hypertension awaiting cardiac transplantation. Thorac Cardiovasc Surg. 2012;60:26–34.PubMedCrossRef
12.
go back to reference Hawkins NM, Petrie MC, Jhund PS, et al. Heart failure and chronic obstructive pulmonary disease: Diagnostic pitfalls and epidemiology. Eur J Hear Fail. 2009;11:130–9.CrossRef Hawkins NM, Petrie MC, Jhund PS, et al. Heart failure and chronic obstructive pulmonary disease: Diagnostic pitfalls and epidemiology. Eur J Hear Fail. 2009;11:130–9.CrossRef
13.
go back to reference • Kwon BJ, Kim DB, Jang SW, et al. Prognosis of heart failure patients with reduced and preserved ejection fraction and coexistent chronic obstructive pulmonary disease. Eur J Hear Fail. 2010;12:1339–44. This study demonstrated in 184 patients with coexistent heart failure (HF) and chronic obstructive pulmonary disease that cardiovascular and pulmonary event-free survival of HF with preserved left ventricular ejection fraction (LVEF) is similar to that of HF with depressed LVEF over 3 years follow-up.CrossRef • Kwon BJ, Kim DB, Jang SW, et al. Prognosis of heart failure patients with reduced and preserved ejection fraction and coexistent chronic obstructive pulmonary disease. Eur J Hear Fail. 2010;12:1339–44. This study demonstrated in 184 patients with coexistent heart failure (HF) and chronic obstructive pulmonary disease that cardiovascular and pulmonary event-free survival of HF with preserved left ventricular ejection fraction (LVEF) is similar to that of HF with depressed LVEF over 3 years follow-up.CrossRef
14.
go back to reference Zeng Q, Jiang S. Update in diagnosis and therapy of coexistent chronic obstructive pulmonary disease and chronic heart failure. Journal of Thoracic Disease. 2012;4:310–5.PubMed Zeng Q, Jiang S. Update in diagnosis and therapy of coexistent chronic obstructive pulmonary disease and chronic heart failure. Journal of Thoracic Disease. 2012;4:310–5.PubMed
15.
go back to reference White DP. Pathogenesis of obstructive and central sleep apnoea. Am J Respir Crit Care Med. 2005;172:1363–70.PubMedCrossRef White DP. Pathogenesis of obstructive and central sleep apnoea. Am J Respir Crit Care Med. 2005;172:1363–70.PubMedCrossRef
16.
go back to reference Kasai T, Bradley TD. Obstructive sleep apnoea and heart failure: Pathophysiologic and therapeutic implications. J Am Coll Cardiol. 2011;57:119–27.PubMedCrossRef Kasai T, Bradley TD. Obstructive sleep apnoea and heart failure: Pathophysiologic and therapeutic implications. J Am Coll Cardiol. 2011;57:119–27.PubMedCrossRef
17.
go back to reference Bradley TD, Floras JS. Sleep apnoea and heart failure: Part ii: Central sleep apnoea. Circulation. 2003;107:1822–6.PubMedCrossRef Bradley TD, Floras JS. Sleep apnoea and heart failure: Part ii: Central sleep apnoea. Circulation. 2003;107:1822–6.PubMedCrossRef
18.
go back to reference • Khayat R, Abraham W, Patt B, et al. Central sleep apnoea is a predictor of cardiac readmission in hospitalized patients with systolic heart failure. J Card Fail. 2012;18:534–40. Prospective observational cohort study of hospitalized patients with systolic heart failure (n = 784) evaluating the impact of sleep disordered breathing on cardiac readmissions. It demonstrated that central sleep apnoea (CSA) is an independent risk factor for 6 months’ cardiac readmissions and that effect size of CSA exceeds that of all known predictors of heart failure readmissions.PubMedCrossRef • Khayat R, Abraham W, Patt B, et al. Central sleep apnoea is a predictor of cardiac readmission in hospitalized patients with systolic heart failure. J Card Fail. 2012;18:534–40. Prospective observational cohort study of hospitalized patients with systolic heart failure (n = 784) evaluating the impact of sleep disordered breathing on cardiac readmissions. It demonstrated that central sleep apnoea (CSA) is an independent risk factor for 6 months’ cardiac readmissions and that effect size of CSA exceeds that of all known predictors of heart failure readmissions.PubMedCrossRef
19.
go back to reference •• Bitter T, Westerheide N, Prinz C, et al. Cheyne-stokes respiration and obstructive sleep apnoea are independent risk factors for malignant ventricular arrhythmias requiring appropriate cardioverter-defibrillator therapies in patients with congestive heart failure. Eur Hear J. 2011;32:61–74. Large-scale long-term study including 472 patients with congestive heart failure after implantation of a cardiac resynchronization device with cardioverter-defibrillator. It demonstrated an association between obstructive sleep apnoea and/or central sleep apnoea and risk for malignant cardiac arrhythmia.CrossRef •• Bitter T, Westerheide N, Prinz C, et al. Cheyne-stokes respiration and obstructive sleep apnoea are independent risk factors for malignant ventricular arrhythmias requiring appropriate cardioverter-defibrillator therapies in patients with congestive heart failure. Eur Hear J. 2011;32:61–74. Large-scale long-term study including 472 patients with congestive heart failure after implantation of a cardiac resynchronization device with cardioverter-defibrillator. It demonstrated an association between obstructive sleep apnoea and/or central sleep apnoea and risk for malignant cardiac arrhythmia.CrossRef
20.
go back to reference Momomura S. Treatment of Cheyne-Stokes respiration-central sleep apnoea in patients with heart failure. J Cardiol. 2012;59:110–6.PubMedCrossRef Momomura S. Treatment of Cheyne-Stokes respiration-central sleep apnoea in patients with heart failure. J Cardiol. 2012;59:110–6.PubMedCrossRef
21.
go back to reference • Sharma BK, Bakker JP, McSharry DG, et al.: Adaptive servo-ventilation for treatment of sleep-disordered breathing in heart failure: A systematic review and meta-analysis. Chest. 2012 Jun 21. [Epub ahead of print]. A systematic search including 14 studies (n = 538) which demonstrated that adaptive servo-ventilation (ASV) in adult patients with heart failure and sleep disordered breathing reduces the apnoea/hypopnoea index and improves cardiac function and exercise capacity, providing a rationale for large-scale randomized controlled trials to assess the clinical impact of ASV on hard outcomes in these patients. • Sharma BK, Bakker JP, McSharry DG, et al.: Adaptive servo-ventilation for treatment of sleep-disordered breathing in heart failure: A systematic review and meta-analysis. Chest. 2012 Jun 21. [Epub ahead of print]. A systematic search including 14 studies (n = 538) which demonstrated that adaptive servo-ventilation (ASV) in adult patients with heart failure and sleep disordered breathing reduces the apnoea/hypopnoea index and improves cardiac function and exercise capacity, providing a rationale for large-scale randomized controlled trials to assess the clinical impact of ASV on hard outcomes in these patients.
22.
go back to reference Udani SM, Koyner JL. The effects of heart failure on renal function. Cardiol Clin. 2010;28:453–65.PubMedCrossRef Udani SM, Koyner JL. The effects of heart failure on renal function. Cardiol Clin. 2010;28:453–65.PubMedCrossRef
23.
go back to reference • El Nahas M. Cardio-Kidney-Damage: a unifying concept. Kidney Int. 2010;78:14–8. A rational theory which claims that the high prevalence of heart failure and chronic kidney disease in the elderly population is likely to reflect the underlying high prevalence of overt and subclinical atherosclerosis and cardiovascular disease.PubMedCrossRef • El Nahas M. Cardio-Kidney-Damage: a unifying concept. Kidney Int. 2010;78:14–8. A rational theory which claims that the high prevalence of heart failure and chronic kidney disease in the elderly population is likely to reflect the underlying high prevalence of overt and subclinical atherosclerosis and cardiovascular disease.PubMedCrossRef
24.
go back to reference • Zoccali C, Goldsmith D, Agarwal R, et al. The complexity of the cardio–renal link: taxonomy, syndromes, and diseases. Kidney International Supplements. 2011;1:2–5. Review article emphasizing the lack of evidence regarding the presence of the cardiorenal syndrome.CrossRef • Zoccali C, Goldsmith D, Agarwal R, et al. The complexity of the cardio–renal link: taxonomy, syndromes, and diseases. Kidney International Supplements. 2011;1:2–5. Review article emphasizing the lack of evidence regarding the presence of the cardiorenal syndrome.CrossRef
25.
go back to reference Smith GL, Lichtman JH, Bracken MB, et al. Renal impairment and outcomes in heart failure: Systematic review and meta-analysis. J Am Coll Cardiol. 2006;47:1987–96.PubMedCrossRef Smith GL, Lichtman JH, Bracken MB, et al. Renal impairment and outcomes in heart failure: Systematic review and meta-analysis. J Am Coll Cardiol. 2006;47:1987–96.PubMedCrossRef
26.
go back to reference Gardner RS, Chong KS, O’Meara E, et al. Renal dysfunction, as measured by the modification of diet in renal disease equations, and outcome in patients with advanced heart failure. Eur Hear J. 2007;28:3027–33.CrossRef Gardner RS, Chong KS, O’Meara E, et al. Renal dysfunction, as measured by the modification of diet in renal disease equations, and outcome in patients with advanced heart failure. Eur Hear J. 2007;28:3027–33.CrossRef
27.
go back to reference Giamouzis G, Butler J, Triposkiadis F. Renal function in advanced heart failure. Congestive Heart Failure. 2011;17:180–8.PubMedCrossRef Giamouzis G, Butler J, Triposkiadis F. Renal function in advanced heart failure. Congestive Heart Failure. 2011;17:180–8.PubMedCrossRef
28.
go back to reference • Giamouzis G, Butler J, Starling RC, et al. Impact of dopamine infusion on renal function in hospitalized heart failure patients: Results of the dopamine in acute decompensated heart failure (DAD-HF) trial. J Card Fail. 2010;16:922–30. Small study in patients with acutely decompensated heart failure which demostrated that the combination of low-dose furosemide and low-dose dopamine (5 μg kg -1   min -1 continuous infusion for 8 hours) is equally effective as high-dose furosemide but associated with improved renal function profile and potassium homeostasis.PubMedCrossRef • Giamouzis G, Butler J, Starling RC, et al. Impact of dopamine infusion on renal function in hospitalized heart failure patients: Results of the dopamine in acute decompensated heart failure (DAD-HF) trial. J Card Fail. 2010;16:922–30. Small study in patients with acutely decompensated heart failure which demostrated that the combination of low-dose furosemide and low-dose dopamine (5 μg kg -1 min -1 continuous infusion for 8 hours) is equally effective as high-dose furosemide but associated with improved renal function profile and potassium homeostasis.PubMedCrossRef
29.
go back to reference Jokinen JJ, Tikkanen J, Kukkonen S, et al. Natural course and risk factors for impaired renal function during the first year after heart transplantation. Journal of Heart and Lung Transplantation. 2010;29:633–40.PubMedCrossRef Jokinen JJ, Tikkanen J, Kukkonen S, et al. Natural course and risk factors for impaired renal function during the first year after heart transplantation. Journal of Heart and Lung Transplantation. 2010;29:633–40.PubMedCrossRef
30.
go back to reference Odim J, Wheat J, Laks H, et al. Peri-operative renal function and outcome after orthotopic heart transplantation. Journal of Heart and Lung Transplantation. 2006;25:162–6.PubMedCrossRef Odim J, Wheat J, Laks H, et al. Peri-operative renal function and outcome after orthotopic heart transplantation. Journal of Heart and Lung Transplantation. 2006;25:162–6.PubMedCrossRef
31.
go back to reference Benck U, Hoeger S, Brinkkoetter PT, et al. Effects of donor pre-treatment with dopamine on survival after heart transplantation: A cohort study of heart transplant recipients nested in a randomized controlled multicenter trial. J Am Coll Cardiol. 2011;58:1768–77.PubMedCrossRef Benck U, Hoeger S, Brinkkoetter PT, et al. Effects of donor pre-treatment with dopamine on survival after heart transplantation: A cohort study of heart transplant recipients nested in a randomized controlled multicenter trial. J Am Coll Cardiol. 2011;58:1768–77.PubMedCrossRef
32.
go back to reference Poelzl G, Ess M, Mussner-Seeber C, et al. Liver dysfunction in chronic heart failure: Prevalence, characteristics and prognostic significance. Eur J Clin Investig. 2012;42:153–63.CrossRef Poelzl G, Ess M, Mussner-Seeber C, et al. Liver dysfunction in chronic heart failure: Prevalence, characteristics and prognostic significance. Eur J Clin Investig. 2012;42:153–63.CrossRef
33.
go back to reference Giallourakis CC, Rosenberg PM, Friedman LS. The liver in heart failure. Clinics in Liver Dsease. 2002;6:947–67. viii-ix.CrossRef Giallourakis CC, Rosenberg PM, Friedman LS. The liver in heart failure. Clinics in Liver Dsease. 2002;6:947–67. viii-ix.CrossRef
34.
go back to reference Moller S, Dumcke CW, Krag A. The heart and the liver. Expert Review of Gastroenterology & Hepatology. 2009;3:51–64.CrossRef Moller S, Dumcke CW, Krag A. The heart and the liver. Expert Review of Gastroenterology & Hepatology. 2009;3:51–64.CrossRef
35.
go back to reference •• Allen LA, Felker GM, Pocock S, et al. Liver function abnormalities and outcome in patients with chronic heart failure: Data from the candesartan in heart failure: Assessment of reduction in mortality and morbidity (charm) program. Eur J Hear Fail. 2009;11:170–7. Evaluation of prevalence and importance of liver function test (LFT) abnormalities in a large (n = 2679) cohort of heart failure patients. Elevated total bilirubin was the strongest LFT predictor of adverse outcome for both the composite outcome of cardiovascular death or heart failure hospitalization and all-cause mortality.CrossRef •• Allen LA, Felker GM, Pocock S, et al. Liver function abnormalities and outcome in patients with chronic heart failure: Data from the candesartan in heart failure: Assessment of reduction in mortality and morbidity (charm) program. Eur J Hear Fail. 2009;11:170–7. Evaluation of prevalence and importance of liver function test (LFT) abnormalities in a large (n = 2679) cohort of heart failure patients. Elevated total bilirubin was the strongest LFT predictor of adverse outcome for both the composite outcome of cardiovascular death or heart failure hospitalization and all-cause mortality.CrossRef
36.
go back to reference •• Ambrosy AP, Vaduganathan M, Huffman MD, et al. Clinical course and predictive value of liver function tests in patients hospitalized for worsening heart failure with reduced ejection fraction: An analysis of the EVEREST trial. Eur J Hear Fail. 2012;14:302–11. Post-hoc analysis of the placebo group of the EVEREST (Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study with Tolvaptan) trial including patients hospitalized for systolic heart failure which demonstrated that baseline and in-hospital changes in serum albumin and total billirubin provide additional prognostic value.CrossRef •• Ambrosy AP, Vaduganathan M, Huffman MD, et al. Clinical course and predictive value of liver function tests in patients hospitalized for worsening heart failure with reduced ejection fraction: An analysis of the EVEREST trial. Eur J Hear Fail. 2012;14:302–11. Post-hoc analysis of the placebo group of the EVEREST (Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study with Tolvaptan) trial including patients hospitalized for systolic heart failure which demonstrated that baseline and in-hospital changes in serum albumin and total billirubin provide additional prognostic value.CrossRef
37.
38.
go back to reference Young JB, Abraham WT, Albert NM, et al. Relation of low hemoglobin and anaemia to morbidity and mortality in patients hospitalized with heart failure (insight from the OPTIMIZE-HF registry). Am J Cardiol. 2008;101:223–30.PubMedCrossRef Young JB, Abraham WT, Albert NM, et al. Relation of low hemoglobin and anaemia to morbidity and mortality in patients hospitalized with heart failure (insight from the OPTIMIZE-HF registry). Am J Cardiol. 2008;101:223–30.PubMedCrossRef
39.
go back to reference Groenveld HF, Januzzi JL, Damman K, et al. Anaemia and mortality in heart failure patients: a systematic review and meta-analysis. J Am Coll Cardiol. 2008;52:818–27.PubMedCrossRef Groenveld HF, Januzzi JL, Damman K, et al. Anaemia and mortality in heart failure patients: a systematic review and meta-analysis. J Am Coll Cardiol. 2008;52:818–27.PubMedCrossRef
40.
go back to reference Adams Jr KF, Patterson JH, Oren RM, et al. Prospective assessment of the occurrence of anaemia in patients with heart failure: Results from the study of anaemia in a heart failure population (STAMINA-HFP) registry. Am Hear J. 2009;157:926–32.CrossRef Adams Jr KF, Patterson JH, Oren RM, et al. Prospective assessment of the occurrence of anaemia in patients with heart failure: Results from the study of anaemia in a heart failure population (STAMINA-HFP) registry. Am Hear J. 2009;157:926–32.CrossRef
41.
go back to reference Tang YD, Katz SD. Anaemia in chronic heart failure: Prevalence, etiology, clinical correlates, and treatment options. Circulation. 2006;113:2454–61.PubMedCrossRef Tang YD, Katz SD. Anaemia in chronic heart failure: Prevalence, etiology, clinical correlates, and treatment options. Circulation. 2006;113:2454–61.PubMedCrossRef
42.
go back to reference Horwich TB, Fonarow GC, Hamilton MA, et al. Anaemia is associated with worse symptoms, greater impairment in functional capacity and a significant increase in mortality in patients with advanced heart failure. J Am Coll Cardiol. 2002;39:1780–6.PubMedCrossRef Horwich TB, Fonarow GC, Hamilton MA, et al. Anaemia is associated with worse symptoms, greater impairment in functional capacity and a significant increase in mortality in patients with advanced heart failure. J Am Coll Cardiol. 2002;39:1780–6.PubMedCrossRef
43.
go back to reference Le Jemtel TH, Arain S. Mediators of anaemia in chronic heart failure. Heart Failure Clinics. 2010;6:289–93.PubMedCrossRef Le Jemtel TH, Arain S. Mediators of anaemia in chronic heart failure. Heart Failure Clinics. 2010;6:289–93.PubMedCrossRef
44.
go back to reference Giamouzis G, Kalogeropoulos A, Georgiopoulou V, et al. Hospitalization epidemic in patients with heart failure: Risk factors, risk prediction, knowledge gaps, and future directions. J Card Fail. 2011;17:54–75.PubMedCrossRef Giamouzis G, Kalogeropoulos A, Georgiopoulou V, et al. Hospitalization epidemic in patients with heart failure: Risk factors, risk prediction, knowledge gaps, and future directions. J Card Fail. 2011;17:54–75.PubMedCrossRef
45.
go back to reference Tang WH, Tong W, Jain A, et al. Evaluation and long-term prognosis of new-onset, transient, and persistent anaemia in ambulatory patients with chronic heart failure. J Am Coll Cardiol. 2008;51:569–76.PubMedCrossRef Tang WH, Tong W, Jain A, et al. Evaluation and long-term prognosis of new-onset, transient, and persistent anaemia in ambulatory patients with chronic heart failure. J Am Coll Cardiol. 2008;51:569–76.PubMedCrossRef
46.
go back to reference Alexandrakis MG, Tsirakis G. Anaemia in heart failure patients. ISRN Hematology. 2012;2012:246915. Epub 2012 Mar 25.PubMedCrossRef Alexandrakis MG, Tsirakis G. Anaemia in heart failure patients. ISRN Hematology. 2012;2012:246915. Epub 2012 Mar 25.PubMedCrossRef
47.
go back to reference Olivares EL, Carvalho DP. Thyroid hormone metabolism in heart failure: Iodothyronine deiodinases in focus. Current Opinion in Endocrinology, Diabetes, and Obesity. 2010;17:414–7.PubMedCrossRef Olivares EL, Carvalho DP. Thyroid hormone metabolism in heart failure: Iodothyronine deiodinases in focus. Current Opinion in Endocrinology, Diabetes, and Obesity. 2010;17:414–7.PubMedCrossRef
48.
go back to reference Ladenson PW, Sherman SI, Baughman KL, et al. Reversible alterations in myocardial gene expression in a young man with dilated cardiomyopathy and hypothyroidism. Proc Natl Acad Sci U S A. 1992;89:5251–5.PubMedCrossRef Ladenson PW, Sherman SI, Baughman KL, et al. Reversible alterations in myocardial gene expression in a young man with dilated cardiomyopathy and hypothyroidism. Proc Natl Acad Sci U S A. 1992;89:5251–5.PubMedCrossRef
49.
go back to reference Klein I, Danzi S. Thyroid hormone treatment to mend a broken heart. J Clin Endocrinol Metab. 2008;93:1172–4.PubMedCrossRef Klein I, Danzi S. Thyroid hormone treatment to mend a broken heart. J Clin Endocrinol Metab. 2008;93:1172–4.PubMedCrossRef
50.
go back to reference Gerdes AM, Iervasi G. Thyroid replacement therapy and heart failure. Circulation. 2010;122:385–93.PubMedCrossRef Gerdes AM, Iervasi G. Thyroid replacement therapy and heart failure. Circulation. 2010;122:385–93.PubMedCrossRef
51.
go back to reference • Cohen-Lehman J, Dahl P, Danzi S, Klein I. Effects of amiodarone therapy on thyroid function. Nature reviews Endocrinology. 2010;6:34–41. Review paper on the pathophyiology identification, and management of amidarone-induced thyroid abnormalities in patients with heart failure.PubMedCrossRef • Cohen-Lehman J, Dahl P, Danzi S, Klein I. Effects of amiodarone therapy on thyroid function. Nature reviews Endocrinology. 2010;6:34–41. Review paper on the pathophyiology identification, and management of amidarone-induced thyroid abnormalities in patients with heart failure.PubMedCrossRef
52.
go back to reference From AM, Leibson CL, Bursi F, et al. Diabetes in heart failure: Prevalence and impact on outcome in the population. Am J Med. 2006;119:591–9.PubMedCrossRef From AM, Leibson CL, Bursi F, et al. Diabetes in heart failure: Prevalence and impact on outcome in the population. Am J Med. 2006;119:591–9.PubMedCrossRef
53.
go back to reference Yancy CW, Lopatin M, Stevenson LW, et al. Clinical presentation, management, and in-hospital outcomes of patients admitted with acute decompensated heart failure with preserved systolic function: A report from the acute decompensated heart failure national registry (ADHERE) database. J Am Coll Cardiol. 2006;47:76–84.PubMedCrossRef Yancy CW, Lopatin M, Stevenson LW, et al. Clinical presentation, management, and in-hospital outcomes of patients admitted with acute decompensated heart failure with preserved systolic function: A report from the acute decompensated heart failure national registry (ADHERE) database. J Am Coll Cardiol. 2006;47:76–84.PubMedCrossRef
54.
go back to reference MacDonald MR, Petrie MC, Varyani F, et al. Impact of diabetes on outcomes in patients with low and preserved ejection fraction heart failure: An analysis of the candesartan in heart failure: Assessment of reduction in mortality and morbidity (CHARM) programme. Eur Hear J. 2008;29:1377–85.CrossRef MacDonald MR, Petrie MC, Varyani F, et al. Impact of diabetes on outcomes in patients with low and preserved ejection fraction heart failure: An analysis of the candesartan in heart failure: Assessment of reduction in mortality and morbidity (CHARM) programme. Eur Hear J. 2008;29:1377–85.CrossRef
55.
go back to reference Kamalesh M, Cleophas TJ. Heart failure due to systolic dysfunction and mortality in diabetes: Pooled analysis of 39,505 subjects. J Card Fail. 2009;15:305–9.PubMedCrossRef Kamalesh M, Cleophas TJ. Heart failure due to systolic dysfunction and mortality in diabetes: Pooled analysis of 39,505 subjects. J Card Fail. 2009;15:305–9.PubMedCrossRef
56.
go back to reference • Al Zadjali MA, Godfrey V, Khan F, et al. Insulin resistance is highly prevalent and is associated with reduced exercise tolerance in nondiabetic patients with heart failure. J Am Coll Cardiol. 2009;53:747–53. This study demonstrated in a cohort of 129 consecutive nondiabetic heart failure patients that 61 % suffer from insulin resistance (IR), IR increases significantly with worsening New York Heart Association functional class, and that the presence of IR is associated with a significantly lower exercise capacity and peak oxygen consumption.CrossRef • Al Zadjali MA, Godfrey V, Khan F, et al. Insulin resistance is highly prevalent and is associated with reduced exercise tolerance in nondiabetic patients with heart failure. J Am Coll Cardiol. 2009;53:747–53. This study demonstrated in a cohort of 129 consecutive nondiabetic heart failure patients that 61 % suffer from insulin resistance (IR), IR increases significantly with worsening New York Heart Association functional class, and that the presence of IR is associated with a significantly lower exercise capacity and peak oxygen consumption.CrossRef
57.
go back to reference Ashrafian H, Frenneaux MP, Opie LH. Metabolic mechanisms in heart failure. Circulation. 2007;116:434–48.PubMedCrossRef Ashrafian H, Frenneaux MP, Opie LH. Metabolic mechanisms in heart failure. Circulation. 2007;116:434–48.PubMedCrossRef
58.
go back to reference Eurich DT, McAlister FA, Blackburn DF, et al. Benefits and harms of antidiabetic agents in patients with diabetes and heart failure: Systematic review. British Medical Journal. 2007;335(7618):497. Epub 2007 Aug 30.PubMedCrossRef Eurich DT, McAlister FA, Blackburn DF, et al. Benefits and harms of antidiabetic agents in patients with diabetes and heart failure: Systematic review. British Medical Journal. 2007;335(7618):497. Epub 2007 Aug 30.PubMedCrossRef
59.
go back to reference Nesto RW, Bell D, Bonow RO, et al. Thiazolidinedione use, fluid retention, and congestive heart failure: A consensus statement from the American Heart Association and American Diabetes Association. Diabetes Care. 2004;27:256–63.PubMedCrossRef Nesto RW, Bell D, Bonow RO, et al. Thiazolidinedione use, fluid retention, and congestive heart failure: A consensus statement from the American Heart Association and American Diabetes Association. Diabetes Care. 2004;27:256–63.PubMedCrossRef
60.
go back to reference Georgiadou P, Adamopoulos S. Skeletal muscle abnormalities in chronic heart failure. Current Heart Failure Reports. 2012;9:128–32.PubMedCrossRef Georgiadou P, Adamopoulos S. Skeletal muscle abnormalities in chronic heart failure. Current Heart Failure Reports. 2012;9:128–32.PubMedCrossRef
61.
go back to reference Strassburg S, Springer J, Anker SD. Muscle wasting in cardiac cachexia. Int J Biochem Cell Biol. 2005;37:1938–47.PubMedCrossRef Strassburg S, Springer J, Anker SD. Muscle wasting in cardiac cachexia. Int J Biochem Cell Biol. 2005;37:1938–47.PubMedCrossRef
62.
go back to reference von Haehling S, Stepney R, Anker SD. Advances in understanding and treating cardiac cachexia: Highlights from the 5th cachexia conference. Int J Cardiol. 2010;144:347–9.CrossRef von Haehling S, Stepney R, Anker SD. Advances in understanding and treating cardiac cachexia: Highlights from the 5th cachexia conference. Int J Cardiol. 2010;144:347–9.CrossRef
63.
go back to reference Duscha BD, Schulze PC, Robbins JL, Forman DE. Implications of chronic heart failure on peripheral vasculature and skeletal muscle before and after exercise training. Hear Fail Rev. 2008;13:21–37.CrossRef Duscha BD, Schulze PC, Robbins JL, Forman DE. Implications of chronic heart failure on peripheral vasculature and skeletal muscle before and after exercise training. Hear Fail Rev. 2008;13:21–37.CrossRef
64.
go back to reference Cicoira M, Zanolla L, Franceschini L, et al. Skeletal muscle mass independently predicts peak oxygen consumption and ventilatory response during exercise in noncachectic patients with chronic heart failure. J Am Coll Cardiol. 2001;37:2080–5.PubMedCrossRef Cicoira M, Zanolla L, Franceschini L, et al. Skeletal muscle mass independently predicts peak oxygen consumption and ventilatory response during exercise in noncachectic patients with chronic heart failure. J Am Coll Cardiol. 2001;37:2080–5.PubMedCrossRef
65.
go back to reference Coats AJ. The “muscle hypothesis” of chronic heart failure. J Mol Cell Cardiol. 1996;28:2255–62.PubMedCrossRef Coats AJ. The “muscle hypothesis” of chronic heart failure. J Mol Cell Cardiol. 1996;28:2255–62.PubMedCrossRef
66.
go back to reference • Rehn TA, Munkvik M, Lunde PK, et al. Intrinsic skeletal muscle alterations in chronic heart failure patients: A disease-specific myopathy or a result of deconditioning? Hear Fail Rev. 2012;17:421–36. Critical review of the evidence for skeletal muscle alterations in CHF, the underlying mechanisms of such alterations and how skeletal muscle responds to training in this patient group.CrossRef • Rehn TA, Munkvik M, Lunde PK, et al. Intrinsic skeletal muscle alterations in chronic heart failure patients: A disease-specific myopathy or a result of deconditioning? Hear Fail Rev. 2012;17:421–36. Critical review of the evidence for skeletal muscle alterations in CHF, the underlying mechanisms of such alterations and how skeletal muscle responds to training in this patient group.CrossRef
67.
go back to reference Rutledge T, Reis VA, Linke SE, et al. Depression in heart failure a meta-analytic review of prevalence, intervention effects, and associations with clinical outcomes. J Am Coll Cardiol. 2006;48:1527–37.PubMedCrossRef Rutledge T, Reis VA, Linke SE, et al. Depression in heart failure a meta-analytic review of prevalence, intervention effects, and associations with clinical outcomes. J Am Coll Cardiol. 2006;48:1527–37.PubMedCrossRef
68.
go back to reference Musselman DL, Evans DL, Nemeroff CB. The relationship of depression to cardiovascular disease: Epidemiology, biology, and treatment. Arch Gen Psychiatry. 1998;55:580–92.PubMedCrossRef Musselman DL, Evans DL, Nemeroff CB. The relationship of depression to cardiovascular disease: Epidemiology, biology, and treatment. Arch Gen Psychiatry. 1998;55:580–92.PubMedCrossRef
69.
go back to reference Jiang W, Alexander J, Christopher E, et al. Relationship of depression to increased risk of mortality and rehospitalization in patients with congestive heart failure. Arch Intern Med. 2001;161:1849–56.PubMedCrossRef Jiang W, Alexander J, Christopher E, et al. Relationship of depression to increased risk of mortality and rehospitalization in patients with congestive heart failure. Arch Intern Med. 2001;161:1849–56.PubMedCrossRef
70.
go back to reference Albert NM, Fonarow GC, Abraham WT, et al. Depression and clinical outcomes in heart failure: An OPTIMIZE-HF analysis. Am J Med. 2009;122:366–73.PubMedCrossRef Albert NM, Fonarow GC, Abraham WT, et al. Depression and clinical outcomes in heart failure: An OPTIMIZE-HF analysis. Am J Med. 2009;122:366–73.PubMedCrossRef
71.
go back to reference Freedland KE, Carney RM, Rich MW. Effect of depression on prognosis in heart failure. Heart Failure Clinics. 2011;7:11–21.PubMedCrossRef Freedland KE, Carney RM, Rich MW. Effect of depression on prognosis in heart failure. Heart Failure Clinics. 2011;7:11–21.PubMedCrossRef
72.
go back to reference • O’Connor CM, Jiang W, Kuchibhatla M, et al. Safety and efficacy of sertraline for depression in patients with heart failure: Results of the SADHART-CHF (sertraline against depression and heart disease in chronic heart failure) trial. J Am Coll Cardiol. 2010;56:692–9. The SADHART-CHF trial was a randomized, double-blind, placebo-controlled trial of sertraline 50 to 200 mg/day (n = 234) versus matching placebo (n = 235) for 12 weeks in patients with systolic heart failure and clinical depression. Although, sertraline was safe, it did not provide greater reduction in depression or improved cardiovascular status among patients with HF and depression.PubMedCrossRef • O’Connor CM, Jiang W, Kuchibhatla M, et al. Safety and efficacy of sertraline for depression in patients with heart failure: Results of the SADHART-CHF (sertraline against depression and heart disease in chronic heart failure) trial. J Am Coll Cardiol. 2010;56:692–9. The SADHART-CHF trial was a randomized, double-blind, placebo-controlled trial of sertraline 50 to 200 mg/day (n = 234) versus matching placebo (n = 235) for 12 weeks in patients with systolic heart failure and clinical depression. Although, sertraline was safe, it did not provide greater reduction in depression or improved cardiovascular status among patients with HF and depression.PubMedCrossRef
73.
go back to reference Dardiotis E, Giamouzis G, Mastrogiannis D, et al. Cognitive impairment in heart failure. Cardiol Res Pract. 2012;2012:595821. Epub 2012 Jun 6.PubMed Dardiotis E, Giamouzis G, Mastrogiannis D, et al. Cognitive impairment in heart failure. Cardiol Res Pract. 2012;2012:595821. Epub 2012 Jun 6.PubMed
74.
go back to reference Vogels RL, Oosterman JM, van Harten B, et al. Profile of cognitive impairment in chronic heart failure. J Am Geriatr Soc. 2007;55:1764–70.PubMedCrossRef Vogels RL, Oosterman JM, van Harten B, et al. Profile of cognitive impairment in chronic heart failure. J Am Geriatr Soc. 2007;55:1764–70.PubMedCrossRef
75.
go back to reference Trojano L. Antonelli Incalzi R, Acanfora D, et al.: Cognitive impairment: A key feature of congestive heart failure in the elderly. J Neurol. 2003;250:1456–63.PubMedCrossRef Trojano L. Antonelli Incalzi R, Acanfora D, et al.: Cognitive impairment: A key feature of congestive heart failure in the elderly. J Neurol. 2003;250:1456–63.PubMedCrossRef
76.
go back to reference Zuccala G, Onder G, Marzetti E, et al. Use of angiotensin-converting enzyme inhibitors and variations in cognitive performance among patients with heart failure. Eur Hear J. 2005;26:226–33.CrossRef Zuccala G, Onder G, Marzetti E, et al. Use of angiotensin-converting enzyme inhibitors and variations in cognitive performance among patients with heart failure. Eur Hear J. 2005;26:226–33.CrossRef
77.
go back to reference Kalogeropoulos AP, Georgiopoulou VV, Butler J. From risk factors to structural heart disease: The role of inflammation. Heart Failure Clinics. 2012;8:113–23.PubMedCrossRef Kalogeropoulos AP, Georgiopoulou VV, Butler J. From risk factors to structural heart disease: The role of inflammation. Heart Failure Clinics. 2012;8:113–23.PubMedCrossRef
78.
go back to reference Silverstein DM. Inflammation in chronic kidney disease: Role in the progression of renal and cardiovascular disease. Pediatr Nephrol. 2009;24:1445–52.PubMedCrossRef Silverstein DM. Inflammation in chronic kidney disease: Role in the progression of renal and cardiovascular disease. Pediatr Nephrol. 2009;24:1445–52.PubMedCrossRef
79.
go back to reference Cottone S, Lorito MC, Riccobene R, et al. Oxidative stress, inflammation and cardiovascular disease in chronic renal failure. Journal of Nephrology. 2008;21:175–9.PubMed Cottone S, Lorito MC, Riccobene R, et al. Oxidative stress, inflammation and cardiovascular disease in chronic renal failure. Journal of Nephrology. 2008;21:175–9.PubMed
80.
go back to reference McNicholas WT. Chronic obstructive pulmonary disease and obstructive sleep apnoea: Overlaps in pathophysiology, systemic inflammation, and cardiovascular disease. Am J Respir Crit Care Med. 2009;180:692–700.PubMedCrossRef McNicholas WT. Chronic obstructive pulmonary disease and obstructive sleep apnoea: Overlaps in pathophysiology, systemic inflammation, and cardiovascular disease. Am J Respir Crit Care Med. 2009;180:692–700.PubMedCrossRef
81.
go back to reference Ryan S, Taylor CT, McNicholas WT. Selective activation of inflammatory pathways by intermittent hypoxia in obstructive sleep apnoea syndrome. Circulation. 2005;112:2660–7.PubMedCrossRef Ryan S, Taylor CT, McNicholas WT. Selective activation of inflammatory pathways by intermittent hypoxia in obstructive sleep apnoea syndrome. Circulation. 2005;112:2660–7.PubMedCrossRef
82.
go back to reference Im SS, Osborne TF. Liver x receptors in atherosclerosis and inflammation. Circ Res. 2011;108:996–1001.PubMedCrossRef Im SS, Osborne TF. Liver x receptors in atherosclerosis and inflammation. Circ Res. 2011;108:996–1001.PubMedCrossRef
83.
go back to reference Iredale JP. Models of liver fibrosis: Exploring the dynamic nature of inflammation and repair in a solid organ. The Journal of Cclinical Investigation. 2007;117:539–48.CrossRef Iredale JP. Models of liver fibrosis: Exploring the dynamic nature of inflammation and repair in a solid organ. The Journal of Cclinical Investigation. 2007;117:539–48.CrossRef
84.
go back to reference Maher JJ, McGuire RF. Extracellular matrix gene expression increases preferentially in rat lipocytes and sinusoidal endothelial cells during hepatic fibrosis in vivo. J Clin Invest. 1990;86:1641–8.PubMedCrossRef Maher JJ, McGuire RF. Extracellular matrix gene expression increases preferentially in rat lipocytes and sinusoidal endothelial cells during hepatic fibrosis in vivo. J Clin Invest. 1990;86:1641–8.PubMedCrossRef
85.
go back to reference Opasich C, Cazzola M, Scelsi L, et al. Blunted erythropoietin production and defective iron supply for erythropoiesis as major causes of anaemia in patients with chronic heart failure. Eur Hear J. 2005;26:2232–7.CrossRef Opasich C, Cazzola M, Scelsi L, et al. Blunted erythropoietin production and defective iron supply for erythropoiesis as major causes of anaemia in patients with chronic heart failure. Eur Hear J. 2005;26:2232–7.CrossRef
86.
go back to reference • Kleijn L, Belonje AM, Voors AA, et al.: Inflammation and anaemia in a broad spectrum of patients with heart failure. Heart. 2012 Jun 22. [Epub ahead of print]. Multicentre randomised clinical trial including patients admitted for heart failure (n = 326), which demonstrated that anaemia (Hb <13 g/dl (men) and <12 g/dl (women)) was present in 40 % (130/326) of the study population and that that the levels of IL-6, hsCRP and sTNFR-1 were significantly higher in anaemic than in non-anaemic patients emphasizing the association between anaemia and inflammation. • Kleijn L, Belonje AM, Voors AA, et al.: Inflammation and anaemia in a broad spectrum of patients with heart failure. Heart. 2012 Jun 22. [Epub ahead of print]. Multicentre randomised clinical trial including patients admitted for heart failure (n = 326), which demonstrated that anaemia (Hb <13 g/dl (men) and <12 g/dl (women)) was present in 40 % (130/326) of the study population and that that the levels of IL-6, hsCRP and sTNFR-1 were significantly higher in anaemic than in non-anaemic patients emphasizing the association between anaemia and inflammation.
87.
go back to reference Garcia C, Feve B, Ferre P, et al. Diabetes and inflammation: Fundamental aspects and clinical implications. Diabetes & Metabolism. 2010;36:327–38.CrossRef Garcia C, Feve B, Ferre P, et al. Diabetes and inflammation: Fundamental aspects and clinical implications. Diabetes & Metabolism. 2010;36:327–38.CrossRef
88.
go back to reference Ehses JA, Ellingsgaard H, Boni-Schnetzler M, Donath MY. Pancreatic islet inflammation in type 2 diabetes: From alpha and beta cell compensation to dysfunction. Arch Physiol Biochem. 2009;115:240–7.PubMedCrossRef Ehses JA, Ellingsgaard H, Boni-Schnetzler M, Donath MY. Pancreatic islet inflammation in type 2 diabetes: From alpha and beta cell compensation to dysfunction. Arch Physiol Biochem. 2009;115:240–7.PubMedCrossRef
89.
go back to reference Hambrecht R, Adams V, Gielen S, et al. Exercise intolerance in patients with chronic heart failure and increased expression of inducible nitric oxide synthase in the skeletal muscle. J Am Coll Cardiol. 1999;33:174–9.PubMedCrossRef Hambrecht R, Adams V, Gielen S, et al. Exercise intolerance in patients with chronic heart failure and increased expression of inducible nitric oxide synthase in the skeletal muscle. J Am Coll Cardiol. 1999;33:174–9.PubMedCrossRef
90.
go back to reference Adams V, Jiang H, Yu J, et al. Apoptosis in skeletal myocytes of patients with chronic heart failure is associated with exercise intolerance. J Am Coll Cardiol. 1999;33:959–65.PubMedCrossRef Adams V, Jiang H, Yu J, et al. Apoptosis in skeletal myocytes of patients with chronic heart failure is associated with exercise intolerance. J Am Coll Cardiol. 1999;33:959–65.PubMedCrossRef
91.
go back to reference Bartalena L, Bogazzi F, Brogioni S, et al. Role of cytokines in the pathogenesis of the euthyroid sick syndrome. European Journal of Endocrinology / European Federation of Endocrine Societies. 1998;138:603–14.PubMedCrossRef Bartalena L, Bogazzi F, Brogioni S, et al. Role of cytokines in the pathogenesis of the euthyroid sick syndrome. European Journal of Endocrinology / European Federation of Endocrine Societies. 1998;138:603–14.PubMedCrossRef
93.
go back to reference Krishnadas R, Cavanagh J. Depression: An inflammatory illness? J Neurol Neurosurg Psychiatry. 2012;83:495–502.PubMedCrossRef Krishnadas R, Cavanagh J. Depression: An inflammatory illness? J Neurol Neurosurg Psychiatry. 2012;83:495–502.PubMedCrossRef
94.
go back to reference • Gorelick PB. Role of inflammation in cognitive impairment: Results of observational epidemiological studies and clinical trials. Ann N Y Acad Sci. 2010;1207:155–62. Review of the observations that have led to the establishment of an association of systemic and brain inflammatory markers on cognitive impairment and dementia.PubMedCrossRef • Gorelick PB. Role of inflammation in cognitive impairment: Results of observational epidemiological studies and clinical trials. Ann N Y Acad Sci. 2010;1207:155–62. Review of the observations that have led to the establishment of an association of systemic and brain inflammatory markers on cognitive impairment and dementia.PubMedCrossRef
Metadata
Title
Prevalence and Importance of Comorbidities in Patients With Heart Failure
Authors
Filippos K. Triposkiadis
John Skoularigis
Publication date
01-12-2012
Publisher
Current Science Inc.
Published in
Current Heart Failure Reports / Issue 4/2012
Print ISSN: 1546-9530
Electronic ISSN: 1546-9549
DOI
https://doi.org/10.1007/s11897-012-0110-z

Other articles of this Issue 4/2012

Current Heart Failure Reports 4/2012 Go to the issue

Prevention of Heart Failure After Myocardial Infarction (M St. John Sutton, Section Editor)

Imaging the Myocardial Microcirculation Post-Myocardial Infarction

Pathophysiology of Myocardial Failure (IS Anand, Section Editor)

Anemia and Iron Deficiency in Heart Failure

Epidemiology of Heart Failure (J Butler, Section Editor)

Trends In Heart Failure Hospitalizations

Pathophysiology of Myocardial Failure (IS Anand, Section Editor)

Growth Differentiation Factor 15 in Heart Failure: An Update

Pathophysiology of Myocardial Failure (IS Anand, Section Editor)

Atrial Fibrillation in Heart Failure

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.